Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "J05AX" (20)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Maraviroc (J05AX09) 2 products
WHO-DDD
DrugBank.ca
L
SIP
IP
CI
Celsentri 150 mg
60 Tablet(s)
615.81
686.15
10 %
Coated tablets: Maravirocum 150 mg
ViiV Healthcare GmbH
A / SL
FB
G
L
SIP
IP
CI
Celsentri 300 mg
60 Tablet(s)
615.81
686.15
10 %
Coated tablets: Maravirocum 300 mg
ViiV Healthcare GmbH
A / SL
FB
G
Maribavir (J05AX10) 2 products
WHO-DDD
L
IP
CI
Livtencity 200 mg
28
5310.32
5756.20
10 %
Coated tablets: Maribavirum 200 mg
Takeda Pharma AG
A / SL
FB
G
L
IP
CI
Livtencity 200 mg
56
10549.25
11131.35
10 %
Coated tablets: Maribavirum 200 mg
Takeda Pharma AG
A / SL
FB
G
Letermovir (J05AX18) 6 products
WHO-DDD
L
IP
CI
Prevymis 240 mg/12 ml
151.93
181.65
10 %
Concentrate for infusion: Letermovirum 240mg / 12ml
MSD Merck Sharp &
Dohme AG
A / SL
FB
G
L
IP
Prevymis 480 mg/24 ml
299.44
342.05
10 %
Concentrate for infusion: Letermovirum 480mg / 24ml
MSD Merck Sharp &
Dohme AG
A / SL
FB
G
L
IP
CI
Prevymis 240 mg
28
3873.11
4228.65
10 %
Coated tablets: Letermovirum 240 mg
MSD Merck Sharp &
Dohme AG
A / SL
FB
G
L
IP
CI
Prevymis 480 mg
28
7647.17
8153.80
10 %
Coated tablets: Letermovirum 480 mg
MSD Merck Sharp &
Dohme AG
A / SL
FB
G
IP
CI
Prevymis 20 mg
30
k.A.
Granulate: Letermovirum 20 mg
MSD Merck Sharp &
Dohme AG
A
FB
G
IP
Prevymis 120 mg
30
k.A.
Granulate: Letermovirum 120 mg
MSD Merck Sharp &
Dohme AG
A
FB
G
Baloxavir Marboxil (J05AX25) 6 products
WHO-DDD
IP
CI
Xofluza 40 mg
k.A.
Coated tablets: Baloxavirum Marboxilum 40 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Xofluza 40 mg
2
k.A.
Coated tablets: Baloxavirum Marboxilum 40 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Xofluza 80 mg
k.A.
Coated tablets: Baloxavirum Marboxilum 80 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Xofluza 2 mg / ml
k.A.
Granulat zur Herstellung einer Suspension zum Einnehmen: Baloxavirum Marboxilum 40 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Xofluza 20 mg
2
k.A.
Coated tablets: Baloxavirum Marboxilum 20 mg
Roche Pharma
(Schweiz) AG
B
FB
G
IP
CI
Xofluza 20 mg
4
k.A.
Coated tablets: Baloxavirum Marboxilum 20 mg
Roche Pharma
(Schweiz) AG
B
FB
G
Bulevirtide (J05AX28) 1 products
WHO-DDD
L
IP
CI
Hepcludex 2 mg
30
5449.37
5898.85
10 %
Dry substance: Bulevirtidum 2 mg
Gilead Sciences
Switzerland Sàrl
A / SL
FB
G
Fostemsavir (J05AX29) 1 products
WHO-DDD
IP
CI
Rukobia 600 mg
60
k.A.
Delayed release tablets: Fostemsavirum 600 mg
ViiV Healthcare GmbH
A
FB
G
Lenacapavir (J05AX31) 2 products
WHO-DDD
L
IP
CI
Sunlenca
2
19544.18
20360.15
10 %
Injection solution: Lenacapavirum 463.5mg / 1.5ml
Gilead Sciences
Switzerland Sàrl
A / SL
FB
G
L
IP
CI
Sunlenca
5
3061.82
3346.35
10 %
Coated tablets: Lenacapavirum 300 mg
Gilead Sciences
Switzerland Sàrl
A / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
